<code id='40060D222D'></code><style id='40060D222D'></style>
    • <acronym id='40060D222D'></acronym>
      <center id='40060D222D'><center id='40060D222D'><tfoot id='40060D222D'></tfoot></center><abbr id='40060D222D'><dir id='40060D222D'><tfoot id='40060D222D'></tfoot><noframes id='40060D222D'>

    • <optgroup id='40060D222D'><strike id='40060D222D'><sup id='40060D222D'></sup></strike><code id='40060D222D'></code></optgroup>
        1. <b id='40060D222D'><label id='40060D222D'><select id='40060D222D'><dt id='40060D222D'><span id='40060D222D'></span></dt></select></label></b><u id='40060D222D'></u>
          <i id='40060D222D'><strike id='40060D222D'><tt id='40060D222D'><pre id='40060D222D'></pre></tt></strike></i>

          explore

          explore

          author:hotspot    Page View:8176
          Ed Silverman on the Breakthrough Summit stage in 2023.
          STAT's Ed Silverman on stage at the STAT Breakthrough Summit in 2023. Sarah Gonzalez for STAT

          In 2023, STAT launched a brand-new home for our subscribers to connect with each other and with their favorite STAT journalists. On STAT+ Connect, you can find job postings; comment on STAT articles (since we have closed comments on article pages); discuss industry events with other people who work in biotech, pharma, public health advocacy, PR, and more; read insights and exclusive material posted by STAT reporters and editors; and watch events, including live interviews and text-based Ask Me Anything chats.

          Last week, Ed Silverman, AKA Pharmalot, hosted an AMA titled “Stump Pharmalot.” During the AMA, Ed discussed gene therapy, his proudest career moments, what he took in high school instead of chemistry, coffee (or, as he calls it, “cups of stimulation”), and more.

          advertisement

          Below, you can find a lightly edited transcript of the conversation.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          explore

          Moonlake's readout produced a cash windfall. Risks remain
          Moonlake's readout produced a cash windfall. Risks remain

          MollyFerguson/STATFortwodaysstartingonSunday,MoonlakeImmunotherapeuticshappilycrunchednumbersandshar

          read more
          Cell therapy fails to slow type 1 diabetes, but safety is established
          Cell therapy fails to slow type 1 diabetes, but safety is established

          AdobeToleranceistheholygrailincalmingautoimmunedisease,atruceintheimmunesystem’sfaultybattleagainstt

          read more
          Dobbs anniversary: the lost opportunity of abortion as health care
          Dobbs anniversary: the lost opportunity of abortion as health care

          NathanHoward/GettyImagesReflectingonthisfirstanniversaryoftheSupremeCourt’sdecisioninDobbstooverturn

          read more

          BIO: Crackdown on China pharma industry would threaten U.S. drug supply

          AdobeU.S.legislationthatwouldsevertieswithChinesedrugmakerswouldjeopardizethedrugsupplyformillionsof